92 related articles for article (PubMed ID: 445608)
21. [Methyl-GAG, an effective cytotoxic drug for treatment of neoplastic exsudates (author's transl)].
Tanneberger S; Matthias M; Rieche K
Arch Geschwulstforsch; 1974; 43(1):68-74. PubMed ID: 4849186
[No Abstract] [Full Text] [Related]
22. [The problem of accidental paravenous application of cytostatics--case history (author's transl)].
Sommer H; Meinhold P
Zentralbl Gynakol; 1981; 103(21):1324-8. PubMed ID: 6798785
[TBL] [Abstract][Full Text] [Related]
23. [Hyperuricaemia--a parameter in the prognosis of gestosis (author's transl)].
Grünberger W; Reinold E
Z Geburtshilfe Perinatol; 1979 Aug; 183(4):249-53. PubMed ID: 539017
[TBL] [Abstract][Full Text] [Related]
24. [Cytostatic therapy of ovarian neoplasms].
Mattsson W
Lakartidningen; 1977 Sep; 74(39):3339-42. PubMed ID: 909354
[No Abstract] [Full Text] [Related]
25. [Clinical situation and therapy of ovarian carcinoma at Gynaecological Hospital of Jena University, between 1967 and 1976 (author's transl)].
Meinhold P; Sommer H; Nöschel H; Günther M
Zentralbl Gynakol; 1981; 103(21):1280-8. PubMed ID: 7324630
[No Abstract] [Full Text] [Related]
26. [The treatment of metastasising mammary carcinoma with drostanolone propionate (masterid) (author's transl)].
von Lieven H; Büll U
MMW Munch Med Wochenschr; 1974 Nov; 116(47):2043-6. PubMed ID: 4216810
[No Abstract] [Full Text] [Related]
27. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer.
Markman M
Gynecol Oncol; 1993 Dec; 51(3):297-8. PubMed ID: 8112634
[No Abstract] [Full Text] [Related]
28. The effect of Milurit on secondary hyperuricaemia following cytostatic treatment in haemoblastosis patients.
Bodrogi I; Bálint I
Ther Hung; 1979; 27(2):77-83. PubMed ID: 494144
[No Abstract] [Full Text] [Related]
29. Preliminary results with the new cytostatic Penberol in ovarian carcinoma.
Novotná J; Andrysek O
Neoplasma; 1980; 27(1):77-82. PubMed ID: 7374860
[TBL] [Abstract][Full Text] [Related]
30. [The serum uric acid level in the Viennese population (author's transl)].
Müller M; Kuzmits R; Frassine I; Lorant P
Wien Klin Wochenschr; 1981 Aug; 93(15):492-500. PubMed ID: 7303691
[TBL] [Abstract][Full Text] [Related]
31. [Drug therapy of ovarian tumors].
Pérez Manga G; Madrigal Alonso L; Beca Figuier JM; Ureña Castro G
Acta Oncol (Madr); 1976; 11(1):27-32. PubMed ID: 952206
[No Abstract] [Full Text] [Related]
32. [Tumors of ovary and testis (author's transl)].
De Jager R
Rev Med Brux; 1980 May; 1(5):315-20. PubMed ID: 6258206
[No Abstract] [Full Text] [Related]
33. [In vitro examinations - a basis of additional cancer therapy (author's transl)].
Schönfelder M
Zentralbl Chir; 1978; 103(15):961-77. PubMed ID: 360723
[TBL] [Abstract][Full Text] [Related]
34. [Treatment-induced complications and frequent errors in cytostatic therapy].
Senn HJ
Schweiz Med Wochenschr; 1978 Aug; 108(32):1216-22. PubMed ID: 675216
[No Abstract] [Full Text] [Related]
35. [Investigations for using cell- and organ culture in sensibility tests for cytostatics in human ovarial-carcinomas (author's transl)].
Hecker D; Saul G; Wolf G
Arch Geschwulstforsch; 1976; 46(1):34-43. PubMed ID: 962500
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of AMSA in patients with advanced ovarian cancer.
Kearsley JH; Coates AS; Fox RM; Tattersall MH; Page J; Levi JA
Cancer Treat Rep; 1982 May; 66(5):1242-3. PubMed ID: 6896295
[No Abstract] [Full Text] [Related]
37. Ploidy studies in ovarian cancer during cytostatic treatment.
Siracký J
Neoplasma; 1969; 16(4):427-33. PubMed ID: 5344228
[No Abstract] [Full Text] [Related]
38. [Current status and future developments in chemotherapy of advanced epithelial ovarian cancers (author's transl)].
Szepesi T
Wien Klin Wochenschr; 1981 Apr; 93(8):251-5. PubMed ID: 6266166
[TBL] [Abstract][Full Text] [Related]
39. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
40. Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients.
Villa A; Parazzini F; Scarfone G; Guarnerio P; Bolis G
Br J Cancer; 1999 Jan; 79(2):373-4. PubMed ID: 9888485
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
